Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 1/2016

01-02-2016 | Letter to the Editor

Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow”

Authors: Samer Tabchi, Marwan Ghosn

Published in: Targeted Oncology | Issue 1/2016

Login to get access

Excerpt

We have carefully reviewed the comments by Dr. de la Fouchardière published in Targeted Oncology [1] pertaining to our suggested dose escalation of regorafenib in patients with metastatic colorectal cancer, and we believe that the author raises several noteworthy questions. …
Literature
1.
2.
Tabchi S, Ghosn M (2015) Regorafenib: start low and go slow. Target Oncol 10:445–7
3.
Grothey A (2015) Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Clin Adv Hematol Oncol 13(8):514–7PubMed
4.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–12CrossRefPubMed
5.
Li J, Qin S, Yau T, Ma B, Pan J, Xu Y et al. (2014) CONCUR: a randomized, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treatment metastatic colorectal cancer (mCRC) [abstract no. O-0023] Ann Oncol 25(suppl 2):ii114–ii115
6.
Tougeron D, de la Fouchardière C, Etienne PL, Dourthe LM, Mineur L, Paule B, Hollebecque A, Tresch E, Spaeth D, Michel P, Dauba J, Laplaige P, Borg C, Bechade D, Clisant S, Phelip JM, Desseigne F, Andre T, Adenis A (2014) REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC) [abstract no. 602P] Ann Oncol 25(suppl 4):iv205–iv206
7.
Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667CrossRefPubMed
8.
Hofheinz R-D, Arnold D, Kubicka S, Prasnikar N, Vogel A (2015) Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat 38(6):300–8CrossRefPubMed
9.
10.
Ducreux MP, Falcone A, Punt CJA, Thaler J, Poehlein CH, Cervantes A (2014) A prospective, observational trial to further assess safety and efficacy of regorafenib in patients with metastatic colorectal cancer (MCRC) in routine clinical practice (CORRELATE) [abstract no. 613TiP]. Ann Oncol. 25(suppl 4):iv209
11.
Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A et al (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27(12):1948–55CrossRefPubMedPubMedCentral
Metadata
Title
Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow”
Authors
Samer Tabchi
Marwan Ghosn
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 1/2016
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-015-0406-5

Other articles of this Issue 1/2016

Targeted Oncology 1/2016 Go to the issue

Original Research Article

Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients

Day-to-Day Practice

HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases

Original Research Article

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study

Adis Drug Evaluation

Lenvatinib: A Review in Refractory Thyroid Cancer

Original Research

Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort

Review Article

Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits